MSLN-targeted CAR-T Cells in Solid Tumors.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2027

Conditions

Mesothelin-positive Advanced Malignant Solid Tumors

Interventions

BIOLOGICAL

Anti-mesothelin CAR-T cells

Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.

All Listed Sponsors

collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT05783089 - MSLN-targeted CAR-T Cells in Solid Tumors. | Biotech Hunter | Biotech Hunter